Hisashi Yamanaka

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies

M. Ohtsuki, T. Hibi, Tsutomu Takeuchi, 2023, Drug Safety.

RANKL: A therapeutic target for bone destruction in rheumatoid arthritis

Yoshiya Tanaka, Hisashi Yamanaka, Sakae Tanaka, 2018, Modern rheumatology.

Interferon-γ Contributes to HLA-B27-associated Unfolded Protein Response in Spondyloarthropathies

R. Terkeltaub, C. Díaz-Torné, L. Harrold, 2013, The Journal of Rheumatology.

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs : results of the phase 2 / 3 , multicentre , randomised , double-blind , placebo-controlled GO-MONO study through 24 weeks

T. Takeuchi, M. Harigai, T. Yoshinari, 2012 .

Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study

N. Sugiyama, K. Sonomoto, Yoshiya Tanaka, 2024, Rheumatology and therapy.